CG
UTHR icon

Cynosure Group’s United Therapeutics UTHR Stock Holding History

Cynosure Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604K Buy
+1,114
New +$627K 0.09% 132
2026
Q1 		– Sell
-1,050
Closed -$512K – 460
2025
Q4 		$512K Buy
+1,050
New +$489K 0.05% 155

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Cynosure Group's UTHR Position: Q2 2026 in Review

Cynosure Group opened a new position in United Therapeutics (UTHR) in Q2 2026: 1,114 shares worth $604K. The stake represents 0.09% of the portfolio and ranks #132 among its holdings. This is a return to the name: Cynosure Group previously reported a position in UTHR as recently as Q4 2025.

Cynosure Group first reported a position in UTHR in Q4 2025 and has held it in 2 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Cynosure Group held 1,114 shares of United Therapeutics worth $604K as of Q2 2026.
  • United Therapeutics was a new Cynosure Group position in Q2 2026.
  • United Therapeutics made up 0.09% of Cynosure Group's portfolio in Q2 2026, its #132 holding.
  • Cynosure Group first reported a position in United Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.